CytomX Therapeutics (NASDAQ:CTMX) Earns "Neutral" Rating from HC Wainwright

CytomX Therapeutics (NASDAQ:CTMX - Get Free Report)'s stock had its "neutral" rating reaffirmed by research analysts at HC Wainwright in a note issued to investors on Monday,Benzinga reports.

CytomX Therapeutics Trading Down 4.6 %

NASDAQ CTMX traded down $0.05 during trading hours on Monday, reaching $1.04. The company had a trading volume of 2,597,837 shares, compared to its average volume of 2,563,905. The stock has a 50-day moving average of $1.14 and a 200 day moving average of $1.47. CytomX Therapeutics has a 1-year low of $0.98 and a 1-year high of $5.85. The stock has a market capitalization of $81.24 million, a P/E ratio of 5.85 and a beta of 1.06.

CytomX Therapeutics (NASDAQ:CTMX - Get Free Report) last posted its earnings results on Thursday, November 7th. The biotechnology company reported $0.07 EPS for the quarter, beating analysts' consensus estimates of ($0.16) by $0.23. CytomX Therapeutics had a net margin of 10.96% and a negative return on equity of 37.72%. The company had revenue of $33.43 million for the quarter, compared to analysts' expectations of $18.92 million. During the same quarter in the prior year, the company posted $0.04 earnings per share. As a group, sell-side analysts predict that CytomX Therapeutics will post -0.29 EPS for the current year.

Institutional Trading of CytomX Therapeutics

Hedge funds have recently made changes to their positions in the business. Assenagon Asset Management S.A. lifted its position in shares of CytomX Therapeutics by 206.0% during the second quarter. Assenagon Asset Management S.A. now owns 1,238,499 shares of the biotechnology company's stock worth $1,511,000 after purchasing an additional 833,825 shares in the last quarter. Susquehanna Fundamental Investments LLC acquired a new stake in shares of CytomX Therapeutics during the first quarter worth about $124,000. Acadian Asset Management LLC lifted its position in shares of CytomX Therapeutics by 1.7% during the first quarter. Acadian Asset Management LLC now owns 2,690,830 shares of the biotechnology company's stock worth $5,863,000 after purchasing an additional 44,640 shares in the last quarter. SG Americas Securities LLC acquired a new stake in shares of CytomX Therapeutics during the first quarter worth about $57,000. Finally, Candriam S.C.A. acquired a new stake in shares of CytomX Therapeutics during the second quarter worth about $256,000. Institutional investors and hedge funds own 67.77% of the company's stock.

About CytomX Therapeutics

CytomX Therapeutics, Inc, an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology.